Form 4: Enfusion Director Michael Spellacy Reports Acquisition of Restricted Stock Units

Director Michael Spellacy reported the acquisition of 13,470 restricted stock units (RSUs) in Enfusion, Inc. on June 13, 2024.

Summary

• Michael Spellacy, a director of Enfusion, Inc., filed a Form 4 on June 17, 2024, reporting a transaction.
• On June 13, 2024, Spellacy acquired 13,470 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• These RSUs were awarded under the Enfusion, Inc. 2021 Stock Option and Incentive Plan.
• The RSUs will vest in full on the earlier of June 13, 2025, or the date of the 2025 annual meeting of stockholders.
• Following the reported transaction, Spellacy directly owns 56,810 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock acquisition. The acquisition of RSUs by a director is generally viewed as a slightly positive sign, indicating confidence in the company.

Positives

• The acquisition of RSUs by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the earlier of June 13, 2025, or the date of the 2025 annual meeting of stockholders, suggesting a continued commitment to the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider ownership.

Key Dates